Patent applications and USPTO patent grants for SIRION THERAPEUTICS, INC..The latest application filed is for "stable aqueous cyclosporin compositions".
Patent | Date |
---|---|
Stable Aqueous Cyclosporin Compositions App 20090286718 - STRINGER; William Francis | 2009-11-19 |
Modulators Of Ocular Oxidative Stress App 20090253745 - MATA; Nathan L. ;   et al. | 2009-10-08 |
Methods And Compositions For Treating Ophthalmic Conditions Via Modulation Of Megalin Activity App 20090098145 - MATA; Nathan L. ;   et al. | 2009-04-16 |
Methods And Compounds For Treating Retinol-related Diseases App 20090088435 - MATA; Nathan L. ;   et al. | 2009-04-02 |
Modulators of Retinol-Retinol Binding Protein (RBP)-Transthyretin (TTR) Complex Formation App 20090054532 - Mata; Nathan L. ;   et al. | 2009-02-26 |
Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation Grant 7,432,307 - Mata , et al. October 7, 2 | 2008-10-07 |
CAGE Code | 5BKX5 | SIRION THERAPEUTICS, INC. SIRION THERAPEUTICS, INC. |
DUNS | 787236061 | SIRION THERAPEUTICS, INC. |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.